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Abstract 
Phagocytes are cells of the immune system that play important roles in phagocytosis, 
respiratory burst and degranulation – key components of innate immunity and response to 
infection. This diverse group of cells includes monocytes, macrophages, dendritic cells, 
neutrophils, eosinophils and basophils – heterogeneous cell populations possessing cell and 
tissue-specific functions of which cellular metabolism comprises a critical underpinning. Core 
functions of phagocytic cells are diverse and sensitive to alterations in environmental- and tissue-
specific nutrients and growth factors. As phagocytic cells adapt to these extracellular cues, 
cellular processes are altered and may contribute to pathogenesis. The considerable degree of 
functional heterogeneity among monocyte, neutrophil and other phagocytic cell populations 
necessitates diverse metabolism. As we review our current understanding of metabolism in 
phagocytic cells, gaps are focused on to highlight the need for additional studies that hopefully 
enable improved cell-based strategies for counteracting cancer and other diseases. 
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Functional diversity in phagocytic cells 
Phagocytic cells, or phagocytes, were first clearly described by Ilya Metchnikoff as 
microphages (neutrophils) and macrophages inside inflamed tissues [1]. Phagocytes consume 
large particles through phagocytosis, which differs from the more common pinocytosis used to 
uptake molecules [2]. Neutrophils and monocytes/ macrophages make up a major part of innate 
immunity, and are required for the phagocytic clearance of pathogens, a theory originally 
suggested by Ilya Metchnikoff [3]. Both neutrophils and macrophages can be derived from bone-
marrow precursors, though it is now well-appreciated that a large number of macrophage 
populations are independently derived from yolk sac or fetal liver precursors, and maintain their 
populations through local proliferation [4]. Regardless of origin, all phagocytes share not only 
their engulfing function, but they also share downstream mechanisms, such as phagolysosome 
formation and respiratory burst [5]. Nonetheless, phagocyte diversity exists because of unique 
functions. This is evident in inflammation, where tissue-resident macrophages recruit 
neutrophils, which subsequently recruit monocytes that differentiate into inflammatory 
macrophages that are eventually cleared by the returning tissue-resident macrophages. Each 
phagocyte performs specific functions that cannot be completely compensated for by other 
phagocytes [6]. Additionally, macrophages can suppress neutrophil functions [7] and tissue-
resident macrophages can suppress infiltrating monocyte-derived macrophage phagocytosis [8] 
to control inflammation for preservation of tissue integrity and limit auto-immunity. We here 
review how recent findings have enhanced our understanding of how myeloid cell subsets meet 
specific metabolic demands in disease. 
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Metabolism underpins myeloid cell function 
 Metabolism is the process whereby cells convert fuel and food into energy and the 
building blocks of life. One of the first major findings in the field of cell metabolism occurred 
when Lois Pasteur determined that bad batches of wine in France were caused by the 
production of lactic acid from sugar [9]. Fifty years later, it was discovered that pyruvate 
formed lactic acid under homeostatic conditions in animals [10], and that lactic acid was 
produced by muscles, under anaerobic conditions [11]. Otto Warburg showed that tumor cells 
could produce lactic acid aerobically, which was later referred to as the Warburg effect [12]. 
Eventually, these observations and others led to the discovery of parallel pathways whereby 
glucose is oxidized, either by the glycolytic pathway whereby pyruvate and energy in the form 
of ATP (adenosine triphosphate) and reduced NADH (nicotinamide adenine dinucleotide) is 
formed [13], or via the pentose phosphate pathway, which yields the formation of NADPH 
(nicotinamide adenine dinucleotide phosphate) and nucleotide precursors such as ribose 5-
phosphate. Subsequently, Hans Krebs and Arthur Johnson determined that pyruvate fed into 
the tricarboxylic acid cycle (TCA) for ATP production [14], a pathway involving oxidative 
phosphorylation (OXPHOS) which is a contributor of energetic metabolism and formation of 
reactive oxygen species (ROS), such as superoxide and hydrogen peroxide. Phagocytic cells, 
when properly stimulated, utilize metabolic pathways via a process referred to as respiratory 
burst to generate ROS necessary for pathogen killing (Table 1). Glycolytically-derived ATP can 
have autocrine effects on activated macrophages, such as the maintenance of mitochondrial 
membrane potential, protection from apoptotic cell death and production of chemokines that 
are in turn important for neutrophil recruitment [15, 16] (Figure 1). 
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Macrophage and dendritic cell metabolism 
Years after the discovery of the Warburg effect, it was appreciated that peripheral blood 
neutrophils and monocytes primarily undergo lactic acid producing glycolysis, while alveolar 
macrophages utilize glycolysis for mitochondrial fueling [17, 18]. In addition to aerobic glycolysis, 
neutrophils also use the pentose phosphate pathway after phagocytosis [19], to produce free 
radicals utilized in the killing of microbes; a mechanism that is also recognized in macrophages. 
After these early findings, the field of phagocyte immunology grew and interest in metabolic 
function was superseded by integral discoveries of novel subsets and functions. We are only now 
beginning to assess the impact of Warburg metabolism in specific cell subsets [20-23]. In 2010, it 
was reported that dendritic cells (DCs) enhance their levels of glycolysis upon sensing of Toll-like 
receptor ligands (Table 1) [24]. This study, supported by insights from lymphocyte 
immunometabolism [25], triggered a dramatic re-evaluation of how metabolism supports 
phagocyte function. This enhancement of glycolysis was attributed to a compensation effect for 
nitric oxide-mediated inhibition of oxidative phosphorylation (OXPHOS) [26], a phenomenon 
additionally reported in macrophages [27]. Importantly, blocking glycolysis in these macrophages 
specifically inhibited their ability to produce the cytokines interleukin 1b [28] and IL-10 (Figure 1) 
[27]. In the case of IL-10, both macrophage and dendritic cell autocrine signaling restricts the 
upregulation of glycolysis [24, 27], and suppresses NO production, limiting subsequent 
reductions in OXPHOS (Table 1) [27]. Additionally, IL-10 can promote mitophagy, in the absence 
of this signal the inflammasome becomes activated by damaged mitochondrial components and 
IL-1b is released, promoting tissue inflammation [29]. 
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While it is known that glycolysis increases within minutes of LPS addition [27], the 
mechanisms that control this immediate impact are incompletely understood. However, it has 
been widely reported that hypoxia inducible factor 1α (HIF1α) can be stabilized after LPS sensing 
in macrophages and maintains glycolysis over the long-term by enhancing glycolytic gene 
expression [28, 30]. HIF1α can work in concert with an isozyme of pyruvate kinase (PKM2) [31]. 
Normally inactive, dimeric/monomeric PKM2 translocates to the nucleus and is involved in the 
activation of HIF1α target genes, reportedly via a kinase activity rather than its enzyme function, 
although this remains controversial [31]. PKM2 is not the only metabolic enzyme to exhibit 
moonlighting activity: aconitase is also known as iron regulatory protein 1 and can control the 
translation of mRNAs containing iron-responsive elements and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) can bind AU-rich elements of mRNA, such as interferon γ. GAPDH is also 
part of the interferon γ-activated inhibitor of translation (GAIT) complex which controls 
inflammatory gene transcription [32]. More studies are required to determine the repertoire of 
metabolic enzyme moonlighting and how this affects phagocyte functions; which will involve 
unraveling the integration of cell function with metabolic demands. 
Mitochondrial OXPHOS is required for alternative activation of macrophages with 
interleukin-4 [33]. Interleukin-4 triggers Stat6/ PPARg mediated changes that suppress the 
pentose phosphate pathway via CARKL [34], elevate glycolysis [35] and enhances OXPHOS 
through increased lipid breakdown and fatty acid oxidation [33, 36] (Figure 1 and Table 1). These 
metabolic processes in resting and IL-4 treated cells are reportedly maintained by CSF-1 or IL-4 
signaling through mTORC2 and IRF4 [35]. Chronic parasitic diseases may also elicit tissue-specific 
changes in metabolic programming. Schistosome worm survival and egg production are highly 
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dependent on OXPHOS and primarily use fatty acids acquired from their hosts to fuel OXPHOS 
via beta-oxidation [37]. The general enhancement in metabolism, along with suppression of the 
pentose phosphate pathway (that supports inflammatory activation via NADPH oxidase) seen 
after IL-4 is expected considering the enhanced metabolic demand and reported anti-
inflammatory properties of IL-4-stimulated macrophages (Figure 1). However, this emphasizes 
the metabolic switch seen with inflammatory activation, where there is increased demand, but 
lower mitochondrial function. 
The suppression of OXPHOS in LPS-activated macrophages could occur through multiple 
mechanisms, including the downregulation of Idh1 [38], deactivation of pyruvate dehydrogenase 
[39] and interferon-regulated gene 1 (Irg1)-mediated itaconate suppression of mitochondrial 
complex II [40]. Suppression of OXPHOS is primarily attributable to NO, as deletion of inducible-
nitric oxide synthase (NOS2) completely restored OXPHOS [27]. NO reportedly disrupts iron-
sulfur centers in metabolic enzymes such as cytosolic aconitase [41], and can specifically inhibit 
cytochrome C oxidase [42]. In contrast, alternative activation of macrophages via IL-4 has been 
linked to a substantial upregulation of the metabolic enzyme arginase (Table 1). This is important 
because arginase and NOS can compete for their substrate, arginine. Arginase has a much lower 
binding affinity for arginine than NOS, but in resting or IL-4 stimulated macrophages its 
expression is greatly larger than NOS. However, activation with LPS results in enhanced NOS 
expression which can now effectively compete with arginase and produce NO [43, 44]. It is 
unknown whether this suppression of OXPHOS is an off-target effect of an anti-microbial agent 
or is actively required for inflammatory macrophage function. It has been argued that the 
shutdown of OXPHOS is required for citrate accumulation,  a major source of extramitochondrial 
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acetyl-CoA (via ATP-citrate lyase) which can fuel lipid production or diffuse through the nuclear 
membrane for histone acetylation [45]. Interestingly, THP-1 monocytes were shown to uptake 
extracellular citrate for maintenance of histone acetylation and enhanced production of pro-
inflammatory cytokines [46] . Therefore, citrate may be an interesting metabolic target, however 
Pdk1 suppression of pyruvate entry into the TCA in activated macrophages seems to oppose 
citrate production, demonstrating that more study is required to dissect these complex 
mechanisms.  
Although it is appreciated that OXPHOS is suppressed 18-24h after LPS (Table 1), this is 
not indicative of the early response to bacterial components. A study by Garaude et al. [47] 
reports that bone marrow-derived macrophages alter their super-complex (quaternary 
combinations of mitochondrial complexes to allow efficient electron transfer) structures after 
sensing live bacteria to favor enhanced complex II activity and produce ROS that is required for 
optimal bacterial killing. Additionally, Mills et al. [48] report that complex II dependent ROS is 
also required for inflammasome activation and production of IL-1b. However, it is still unclear is 
how these metabolic changes in macrophages translate into in vivo metabolic environments and 
whether a therapeutic window can be achieved. 
In summary, metabolic differences between classically- and alternatively-activated 
macrophages clearly demonstrates the importance and linkage between metabolism and cellular 
function [49]. Increased glycolytic flux in M1 macrophages maintains ATP levels for biosynthesis, 
favors NADPH production by the pentose phosphate pathway and results in nitric oxide and ROS 
generation (Figure 1). Conversely, M2 macrophages generate ATP primarily through OXPHOS and 
fatty acid oxidation, which can be sustained for longer periods of time. Macrophages modulate 
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their metabolic pathways due to alterations in their environment and thus their cellular 
phenotype is sensitive to metabolic adaptations. 
 
Unique characteristics of tissue-resident macrophage metabolism 
Now considered distinct from traditional monocyte-derived macrophages, tissue-resident 
macrophages, in the majority of tissues can be derived from yolk sac or fetal liver precursors, and 
maintain their populations through local proliferation [4]. However, monocytes can eventually 
replenish some of these populations to become long-lived cells [50], and gut macrophages are 
constantly renewed by monocytes [51]. The full impact of a macrophage’s origin on function has 
yet to be elucidated, however it is known that monocyte-derived cells are less resistant to 
radiation induced DNA damage than non-myeloid derived macrophages such as Langerhans cells 
[52]. Regardless of cellular origin, the mechanisms that govern macrophage differentiation and 
adaptation to specific niches will facilitate understanding of tissue-specific physiology, which is 
distinct from studying these cells after long term in vitro culture. 
Tissue-resident macrophages play important roles in tissue and organismal metabolism. 
This is evident in metabolic organs such as the liver, where Kupffer cells engage in iron metabolic 
homeostasis [53] and fat storage in adipose tissue [54]. In the context of cellular energetic 
metabolism, however, very little has been recorded in tissue-resident macrophages. An intricate 
understanding of cell metabolic cross-talk in privileged sites like the brain has emerged. Examples 
include the mechanisms by which astrocytes, part of the blood brain barrier, convert blood sugar 
into lactate, a usable fuel for neurons, and the continual uptake and recycling of neuronal 
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secreted neurotransmitters N-acetyl-aspartate (NAA) and glutamate by glial cells [55, 56]. In the 
latter case, the oligodendrocytes specifically express the aspartoacylase enzyme required for 
NAA breakdown. The catabolism of NAA is needed to restrict the neurotransmitter level, but it is 
additionally vital for oligodendrocyte production of the sphingomyelin that is required for 
effective myelination of the neurons; impairment of aspartoacylase results in Canavan’s disease 
[57]. Although these interactions are intriguing, the relevance of these intercellular metabolic 
connections in tissues readily accessible to blood nutrients remains poorly understood.  
Recent studies in the peritoneal cavity have further enhanced our view on how cells 
metabolically adapt to maintain tissue homeostasis. The peritoneum is a serosal nexus of well 
vascularized distinctive organs, and the professional tissue-resident macrophages here can 
invade adjacent organs to facilitate tissue repair [58]. Peritoneal macrophages have a unique 
gene signature controlled by epigenetic alterations brought about by the peritoneal environment 
[59, 60]. One such factor is the metabolite retinoic acid, which is manufactured by omental tissue 
from vitamin A [61]. Retinoic acid acts through RXR receptors to activate Gata6 expression, which 
is a master controller of the peritoneal macrophage phenotype [61-63]. This not only has 
functional contexts for the cells, but Gata6 expression is required for maintenance of peritoneal 
B1 cells through transforming growth factor b2 secretion, these B1-cells participate in gut IgA 
production, making this an important pathway for immune protection of the organism [61]. A 
recent study by our laboratory showed that the peritoneal cavity also contains NAA [64], which 
is noteworthy because Gata6-driven aspartoacylase is also expressed in peritoneal tissue-
resident macrophages [62]. It is likely that the peritoneal tissue-resident macrophages play a role 
in clearance of peritoneal NAA, but more study is required to elucidate the role of NAA in the 
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peritoneum. Additionally, our study [64] highlighted that the peritoneum contains glutamate, 
which can be utilized by peritoneal tissue-resident macrophages during phagocytosis to fuel 
mitochondrial function for enhanced ROS production (Table 1). This mechanism is dependent on 
protein kinase C with subsequent ROS production almost completely dependent on 
mitochondrial complex III activity. Thus, peritoneal macrophages are unlikely to rely on reverse 
electron transfer for their considerable ROS production, as has been reported with bone-marrow 
derived macrophages. Additionally, unlike bone-marrow derived macrophages [47], peritoneal 
macrophages are poised to utilize complex II without the additional need for microbial sensing 
mechanisms. These differences inform us that the metabolic set up of various cell subsets in situ 
is likely to differ from studies in vitro, and care needs to be taken in the interpretation of these 
results. The source of peritoneal glutamate and its effects on other peritoneal cells are still 
unknown, though it is well placed to engage glutamate receptors, perhaps on parasympathetic 
neurons; meaning that macrophage metabolic demands can alter the physiology of the 
peritoneal tissue. 
Peritoneal macrophages are dependent on CSF-1, which acts as a survival and/or growth 
factor [65], and it has been reported that bone marrow-derived macrophages also utilize CSF-1 
signaling to maintain metabolic pathways via mTORC2 and IRF-4 [66]. However, a recent study 
[67] reveals that these mechanisms can become complex in the peritoneal environment. Retinoic 
acid-driven Gata6 expression maintains the peritoneal macrophage phenotype, but also 
competes with mTORC2, which can downregulate Gata6 expression via phosphorylation of 
FOXO1. This inhibits proliferation and survival, and is seemingly an oxymoron, as CSF-1 is required 
for survival, but could actively signal mTORC2 to restrict survival. It is likely that Gata6 and CSF-1 
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are both acting to keep the cell relatively quiescent, but this is modified during inflammation, so 
that mTORC2 can repurpose the metabolic programming to facilitate inflammatory function, 
although this may result in the death of some cells, as has been theorized in the macrophage 
disappearance reaction [68]. Another example of the importance of cell energetics in tissue-
resident macrophages comes from a recent study by Ulland et al. [69]. TREM2 signaling was 
required to activate mTOR and AMPK to manage the increased energetic demands of microglia 
in brain inflammation. In this case, the authors fixed the microglial energy deficit through dectin-
1 signaling or in vivo cyclocreatine addition, this reduced aberrant autophagy and reduced 
neuronal damage. This study shows that understanding both macrophage functions and 
metabolic demands can lead to metabolically targeted treatment strategies. 
These studies on tissue resident macrophages emphasize the need for investigating 
phagocyte functions in context with their tissue niche environment. While studies on isolated 
cells are extremely useful in interrogating cell signaling pathways, they may ultimately constrain 
our understanding of how tissue systems work in concert to maintain or restore homeostasis, 
which in turn will hinder our ability to treat disease. It is expected that additional integrative 
approaches to studying cell interactions with the environment will combine our current 
understanding of phagocyte function with tissue physiology. 
 
Neutrophils 
Neutrophils are a specialized subset of phagocytes which are abundant, short lived, highly 
motile and aggressively defend against pathogens. Neutrophils represent the most numerous 
leukocyte in human blood with a high turnover rate with as much as 60% of the bone marrow 
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committed to their development [70] and as many at 109/kg released from the bone marrow 
each day and a further 6x1011 prepared for release [71]. Although neutrophils were thought to 
survive only hours in the circulation [72], recent studies have shown they can last days in 
circulation [73] and subsequently their roles in homeostasis [74] and diseases such as cancer [75] 
are being re-evaluated. Neutrophils have very low transcriptional and translational activity [76] 
and have the majority of proteins they require for function preassembled and packaged in 
cytoplasmic granules [77]. This preparation allows neutrophils to instantly respond to activating 
signals without the need to engage in transcription and protein translation. However, this lack of 
cellular activity and short life span has led to a similar assumption of neutrophil metabolism, as 
neutrophils, for the most part, can be assumed to not require the complex metabolic networks 
that other cells use to maintain life spans and engage in long term functions. Hence, an 
oversimplification which has plagued them in the wider immunology field has continued into 
immunometabolism, leaving neutrophils often overlooked as a metabolically simple cell, wholly 
dependent on glycolysis. 
These initial assumptions of glucose dependence have some merit and are based on early 
observations of phagocyte metabolism. For example, neutrophils contain far fewer number of 
active mitochondrial compared to other professional phagocytes such as macrophages [78, 79]. 
In addition to this, studies have reported that, as part of their maturation process, neutrophils 
lose cytochrome C expression [80], a vital component of the electron transport chain and 
maintain mitochondrial membrane potential to engage in apoptosis [80]. Furthermore, 
neutrophil effector functions were shown to be highly dependent on glucose. Upon activation, 
neutrophils engage in the generation of large amounts of ROS, via respiratory burst. Thus, 
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neutrophils, like monocytes and macrophages, use the NADPH oxidase (NOX) system [81] which 
uses molecular oxygen and NADPH to produce superoxide (Figure 1). This is in turn processed 
into other downstream ROS by the action of enzymes such as myeloperoxidase. This activity is 
essential for neutrophil function and competent protection against microbes. To this end 
neutrophils engage their propensity for glucose metabolism to fuel the pentose phosphate 
pathway and glucose-6-phosphate dehydrogenase, which catalyzes the reaction of glucose-6-
phosphate (G6P) to 6-phospho- gluconolactone, yielding NADPH. Patients with mutations in this 
enzyme suffer from G6P dehydrogenase deficiency (G6PDD) which severe forms of this mutation 
can lead to reduced NADPH levels required to effectively run the NOX system, leading reduced 
neutrophil ROS and increased susceptibility to infection [82, 83]. Additionally, mutations which 
affect neutrophil handling of the glucose derivative, G6P, via the G6P transporter leads to a 
severe congenital neutropenia [84]. This can lead to arrest in neutrophil development and 
dysfunction of respiratory burst and chemotaxis [85]. This loss of G6P/glucose homeostasis in 
these neutrophils leads to reduced glucose uptake, impaired lactate, ATP and NADPH production, 
activation of HIF-1a/PPARg pathways and cellular dysfunction [83]. Neutrophils have also been 
shown to store the glucose polymer glycogen at the inflammatory site, perhaps suggesting that 
in some circumstances neutrophils store glucose for later use (Figure 1) [86]. These studies 
underline the importance of glucose in neutrophil metabolism and its effects on effector 
function. 
Neutrophil mitochondria have also been shown to play a role in important cellular 
functions. Despite initial observations of mitochondrial loss during development, recent studies 
have demonstrated that mitochondrial function [87] and a switch from glycolysis to fatty acid 
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oxidation is required for effective neutrophil differentiation in vivo (Figure 1) [88]. Furthermore, 
other studies have now suggested active networks of mitochondria are present in circulating 
neutrophils and are required for responses such as chemotaxis, through release of low-level cell 
signaling ROS [89]. Although disruption of mitochondrial function was not shown to affect 
respiratory burst or phagocytosis initially, prolonged disruption of mitochondrial membrane 
potential inhibited respiratory burst, suggesting a steady state role for mitochondrial metabolism 
in neutrophils [90]. Additionally, mitochondrial-dependent autocrine purinergic signaling is 
important for neutrophil activation. Despite requiring glycolysis to engage in prolonged signaling, 
mitochondria appear to be essential in initiating this signaling response [91].  
Mitochondria can also act as a ROS producing organelle [92]. This mechanism has been 
shown to play a role in host defense from pathogens by macrophages [47, 93]. This is mechanism 
is particularly interesting when considering patients with chronic granulomatous disease (CGD). 
CGD is a heterogeneous disease leading to defects in the ROS producing NOX system. This lack of 
phagocyte ROS leaves patients highly susceptible to pathogens. Interestingly, studies in both 
mice and humans demonstrated that treatment with the proliferator–activated receptor (PPAR)-
g agonist pioglitazone enhanced mitochondrial ROS in NOX deficient neutrophils. This induced 
mitochondrial ROS and partially restored the ability of NOX deficient neutrophils to combat 
staphylococcus aureus, demonstrating a potential compensatory mechanism of mitochondria to 
support NOX activity [94]. Neutrophil extracellular traps (NETs) are of recent interest to the field 
of neutrophil metabolism. These structures consist of DNA and granules and are used to trap and 
kill invading pathogens, a process termed NETosis. NETosis requires ROS production, and as 
described above, involves a metabolic shift towards PPP and G6PD activity to fuel NOX activity 
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(Figure 1) [95]. Indeed, G6PDD leads to a reduced ability of neutrophils to produce NETs [96]. 
Further studies have revealed that mitochondrial function also plays a role in NET formation 
(Table 1). Although still largely dependent on increased glucose uptake and metabolism, 
withdrawal of glutamine or disruption of mitochondrial ATPase was also shown to partially 
reduce NET formation [97]. This suggested a glutamine-fueled mitochondrial-dependent stage to 
NETosis in neutrophils. Indeed, during the engagement of NETosis, neutrophil mitochondria 
translocate to the cell surface and become hyperpolarized releasing ROS [98]. In addition to 
mitochondrial ROS involvement, mitochondrial components, such as oxidized mitochondrial 
DNA, have also been shown to be a component of NETs [99]. 
Despite the above studies, we still know very little of how neutrophils adapt their 
metabolism to function in the environment around them and whether this can be altered in 
disease. Recent data from our laboratory has shown that neutrophil mitochondrial metabolism 
supports respiratory burst by fueling NOX with NADPH [100]. One important distinction between 
neutrophils and macrophages is the plasma membrane association of NOX in neutrophils (Figure 
1) [101]. Thus, plasma membrane associated NOX in neutrophils is not coupled to mitochondrial 
metabolism. Neutrophils which possess a relatively greater mitochondrial mass, such as 
immature neutrophils, maintain NADPH production via fatty acid dependent mitochondrial 
function when glucose metabolism was restricted [100]. This effect was particularly prominent 
in tumor-elicited neutrophils which had significantly enhanced mitochondrial mass, function and 
associated fatty acid metabolism. Neutrophils require fatty acid oxidation and mitochondrial 
respiration for differentiation from the bone marrow [88] and immature neutrophilic cell subsets 
are recruited to tumors [102]. In consideration of this, we hypothesize that like macrophages 
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[64], neutrophil mitochondria may contribute to respiratory burst in glucose-deprived 
environments such the tumor microenvironment. This could be either by direct ROS contribution 
[94] or citrate export from the mitochondria and subsequent IDH1 activity to supply NADPH fuel 
for NOX. Concordantly, immature neutrophils would have a functional advantage, as they are no 
longer wholly dependent on glucose metabolism to maintain effector functions. Since low-
density, possibly immature, neutrophils more readily engage in mitochondria-dependent NET 
formation [103], the heterogeneity in neutrophil morphology, surface marker expression and 
metabolism may be a dictating factor of neutrophil functional outcome. It is important to 
consider that heterogeneous neutrophil subsets may be metabolically adapted into differing 
tissue niches, especially during chronic inflammation. As numerous neutrophil subsets are being 
discovered and better characterized in both steady state and disease [104], it is intriguing to 
hypothesize that these subsets are targetable due to their differing metabolic architecture. 
 
Adaptations of phagocyte metabolism in cancer 
As mentioned, phagocytic cells adapt to specific microenvironments in their utilization of 
fuels to derive cellular metabolism. Moreover, all cells are sensitive to alterations in their 
microenvironment, thus it is clear that metabolic alterations in immune cells underlies a central 
component of pathology. In cancer, the competitive advantage for tumor cells to consume 
nutrients such as glucose has the profound potential to limit availability of fuels necessary for 
immune cell function [105]. Although the metabolism of tumor cells has been well described, it 
is noteworthy that the effects of tumor cells upon the immunometabolism of macrophages and 
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other immune cells is incompletely understood. Small amounts of extracellular citrate can be 
incorporated into tumor cells at physiological levels found in the blood, and this is increased in 
hypoxic glucose-starved conditions that match the tumor setting [106]. As mentioned previously, 
activated macrophages accumulate citrate [38], thus, it would be interesting to hypothesize that 
macrophage activation in the tumor setting can supply extracellular citrate for tumor 
progression. Additionally, the high levels of glycolysis in tumors yields lactic acid which may 
polarize tumor-associated macrophages into a pro-tumor, M2-like phenotype [107]. There are 
presumably many undiscovered fuels and signals associated with tumors involved in metabolic 
alterations and polarization in macrophages. Other mechanisms by which tumor-associated 
macrophage differentiation may be facilitated are highlighted by the caspase-dependent 
cleavage of peroxisome proliferator-activated receptor gamma (PPARg), which results in the 
inhibition of fatty acid oxidation and accumulation of TAM-promoting lipid droplets [108]  
Another intriguing mechanism by which tumors may influence phagocyte metabolism is by 
alterations in expression or function by cell surface proteins, such as HSP90 [109]. Although 
HSP90 is a typical cytoplasmic/nuclear chaperone protein capable of regulating mitophogy and 
cytokine production in macrophages, it also comprises a pool of cell surface associated proteins 
potentially regulated by extracellular cues such as tumors. In dendritic cells, the TLR-mediated 
detection of danger signals and subsequent cellular responses to pathogens is in part through 
alterations in mitochondrial metabolism [24, 26]. The tissue-specific composition and availability 
of fuels also underlies niche-specific alterations in metabolism [64]. Wenes, et al show that 
tumor-associated macrophages contribute to abnormal blood vessel formation and 
angiogenesis, through the utilization of large amounts of glucose and inhibition of mTOR that 
19 
 
promotes quiescence of vascular endothelial cells [110]. In that study, the hypoxia-inducible 
mTOR inhibitor, REDD1 plays an important role in regulating glucose utilization by tumor-
associated macrophages and may be an attractive metabolic target, since REDD1-targeting 
resulted in normalization of tumor vessels and reduced metastases. Tissues such as the 
peritoneal cavity are frequently the site of tumor development and metastasis, and as such there 
is considerable potential cross-talk between developing tumors and tissue-resident macrophages 
that normally play important roles in homeostasis and immune surveillance. We recently showed 
that cross-talk between tumor cells and resident macrophages of the peritoneum induces 
metabolic alterations in the resident macrophage population which in turn regulates 
macrophage effector function and tumor progression [111]. In ovarian carcinoma, which 
metastasizes to and grows progressively in the peritoneum, altered metabolite expression is 
highlighted by the dramatic upregulation of the metabolite, itaconic acid, in resident 
macrophages [111]. Itaconic acid was already recognized as an important metabolite due to its 
ability to inhibit the glyoxylate shunt, an anabolic variation of the TCA that is essential for 
bacterial growth [112]. In mammalian cells, itaconic acid inhibits glycolysis and the TCA, the latter 
by acting on succinate dehydrogenase [113, 114]. Itaconic acid is robustly induced by 
proinflammatory stimuli such as IFNg or LPS [115]. In our studies, itaconic acid was a critical 
component of the tumor-induced enhancement of fatty acid oxidation-fueled OXPHOS in 
resident macrophages and the generation of pro-tumor ROS [111]. The identification of 
metabolites such as itaconic acid and REDD1 as potential therapeutic targets supports the need 
for additional research into the multitude of ways tumor and host cellular responses are 
regulated by metabolism. 
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Myeloid derived suppressor cells  
Myeloid derived suppressor cells (MDSC) are defined as a heterogeneous population of 
phagocytes which inhibit anti-tumor immunity through various mechanisms [116]. In mice, these 
cells are defined by Gr-1 positive staining. This has led to extreme confusion as Gr-1 identifies 
both Ly-6G and Ly-6C expressed primarily on neutrophils and monocytes respectively. This lack 
of differentiation makes the reported studies hard to interpret, particularly from a metabolic 
standpoint. Some studies have further subdivided the Gr-1 positive populations using Ly6G and 
Ly6C to identify the granulocytic (g)-MDSC and monocytic (m)-MDSC respectively [117]. 
Difference between these MDSC subsets and classically identified neutrophils and monocytes 
remain ill-defined and may indeed represent an activated state of these subsets. Human MDSC 
remain even harder to define as there is no equivalent to Gr-1 which detects both monocytic and 
granulocytic cells together. 
Regardless of their identity, studies have identified metabolic underpinning to the 
differentiation, maintenance and suppressive nature of these heterogeneous phagocytic 
populations. In vitro differentiation of BM precursors to MDSC like phenotype using GM-CSF and 
IL-6 enhanced glucose uptake and anaerobic glycolysis as well as glutamine utilization [118]. 
Furthermore, recent studies have demonstrated that tumors increased expression of genes 
involved in glycolysis in both g- and m- MDSC subsets [119]. This increased glycolysis was required 
to promote expansion and prevent apoptosis of MDSC. 
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Fatty acid metabolism has also been shown to be a vital component of MDSC 
development and function (Table 1). Conditioned media and diets high in poly-unsaturated fatty 
acids have been shown to promote development of g-MDSC subsets in vitro and in vivo [120]. 
Hossain et al demonstrated that MDSC populations increase fatty acid uptake, mitochondrial 
mass and oxygen consumption rates at the tumor site [121]. This fatty acid dependent metabolic 
function was found to be required for their suppressive function and cytokine production. 
Interestingly this study suggested that fatty acid uptake was increased in both Ly-6G and Ly-6C 
positive cells at the tumor site, suggesting that several subsets of activated phagocyte may 
become more oxidative in the tumor microenvironment. 
MDSC have also shown to alter the metabolic milieu of the environment around them to 
fulfill their suppressive function. Many of these studies highlight the ability of MDSC to deplete 
the local niche of amino acids, required for T cell activity. T cells require the amino acid cysteine 
for protein synthesis and activation following antigen presentation. However, T cells struggle to 
acquire this metabolite themselves due to the lack enzyme systems required to form cysteine or 
the transporters which import the oxidized analogue cystine from the extracellular environment. 
T cells are therefore wholly dependent on the activity of supporting phagocytes, such as dendritic 
cells and macrophages, which create cysteine by reducing imported cystine or by converting 
methionine to cysteine by the action of cystathionase. These phagocytes then export cysteine 
which is utilized by the T cells during activation [122]. MDSC disrupt this metabolic corporation 
by consuming extracellular cystine and failing to generate and export cysteine [123]. Therefore, 
the accumulation of MDSC depletes the extracellular environment of cysteine and renders T cells 
inactive. MDSC can also engage in heightened arginine metabolism to modify a tumor milieu. 
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This occurs by enhanced arginase-1 (ARG1) activity which depletes extra cellular arginine, 
rendering T cell inactive through down regulation of TCR zeta (Table 1). This mechanism was 
originally described in macrophages [124], suggesting that many aspects of MDSC metabolic 
activity are not unique to this population. In addition to its ability to deplete arginine, the activity 
of the arginase was found to be essential in controlling the glucose and glutamine uptake as well 
as TCA activity and subsequent AMP-kinase activity of in vitro MDSC models [118]. MDSC have 
been shown to deplete extracellular tryptophan by the action of the enzyme indoleamine 2,3-
dioygenase (IDO), further contributing to an immune suppressive tumor niche [125].  MDSC also 
generate reactive free radicals such as ROS and NO which have detrimental effects on T cell 
activity. The MDSC in a similar manner to neutrophils and macrophages produce large quantities 
of ROS vis NADPH oxidase [126] [127]. Whereas, g-MDSC appear to be a greater source of 
arginase activity in tumors, the metabolism of L-arginine to citrullene and nitric oxide (NO) by 
nitric oxide synthase (NOS) is a metabolic pathway more associated with the m-MDSC [128] 
[129]. This production of NO is also inhibitory to T cell activity [130]. 
 
Metabolism of other Phagocytes 
As our understanding of phagocyte metabolism continues to develop, it will be intriguing 
to consider the metabolism of other less well studied phagocytes, such as osteoclasts, 
eosinophils, mast cells and basophils. Osteoclasts, in a similar manner to resident macrophages, 
possess a high degree of metabolic plasticity, with a high glycolytic and mitochondrial capacity, 
that enables them to carry out effector function in diverse and often hostile environments [131]. 
With numerous bone pathologies associated with aberrant osteoclast activity, further 
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understanding of their metabolism may lead to novel therapeutic strategies for diseases such as 
osteoporosis. Similar to neutrophils, other granulocytes such as eosinophils and mast cells also 
have a high propensity for glucose metabolism and the pentose phosphate pathway [132], with 
mast cells also engaging in glycogen metabolism [133]. However, mast cells were also found to 
utilize glucose metabolism to synthesize lipids and, more recently, oxidative phosphorylation has 
been demonstrated to be required for mast cell effector functions such as degranulation and 
cytokine production [134]. Furthermore, abnormal tryptophan metabolism in eosinophils was 
found to be a critical component in eosinophilia-myalgia syndrome (EMS) [135], further 
suggesting that an improved understanding of granulocyte metabolism may potentially unveil 
pathological drivers and potential drug targets. 
 
Concluding Remarks 
Metabolic adaptation to environmental cues is an intrinsic property of all cells. 
Mitochondrial function is essential for immune cell function and as such, cells must adapt to 
changes in resources in their surroundings. Immune cells exhibit niche-specific alterations in their 
metabolism that are dependent on tissue-specific concentrations of metabolic fuels such as 
glucose, glutamate and glutamine that underlie distinctive tissue-specific functions. For example, 
metabolic adaptation of tissue-resident phagocytic cells is necessary for these cells to carry out 
cellular processes necessary for tissue homeostasis, response to pathogens and localized 
inflammatory responses.  As cellular environments change during pathogenesis, immune cells 
must adapt to alterations in the availability of nutrients and other environmental changes. The 
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metabolic reprogramming of phagocytic cells during tumor development, for example, is a major 
contributing factor to altered and, in many cases, co-opted, cellular function. 
As we continue to learn more about metabolic programming in diverse immune subsets, 
the deployment of metabolic-based strategies aimed at immune cell reprogramming becomes 
more of a feasible means by which cancer and other diseases may be treated. As such, there is a 
paucity of information on the metabolism of phagocytic cells such as eosinophils, basophils and 
neutrophils. Moreover, the considerable degree of functional heterogeneity among monocyte, 
neutrophil and other phagocytic cell populations indicates a spectrum of metabolic function 
exists in these cells. There is considerable need to refine our understanding of metabolic function 
in these cells so that metabolic-based therapies become a feasible strategy to treat cancer and 
other diseases. 
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 Glycolysis PPP OXPHOS/ ETC TCA cycle Fatty acids Amino acids 
BMDM + LPS/IFNγ Enhanced: Survival and 
Cytokines[28] 
Enhanced: ROS, NO, Redox, 
RNA[34] 
Shut down via NO[27] and 
itaconic acid[113] 
Broken[38]: Itaconic acid, 
Lipids, Cytokines[28] 
Enhanced FAO & FAS: 
Cytokines[136, 137] 
Glutamine: Not needed for 
phenotype[38] 
Arginine: NO production[27] 
BMDM + IL-4 Enhanced: Phenotype 
maintenance[35] 
Shut down via CARKL: 
Phenotype maintenance[34] 
Enhanced: ATP, Phenotype 
maintenance[33] 
 
Enhanced FAO & FAS: 
Phenotype 
maintenance[33, 36] 
Glutamine: protein 
modifications maintain 
phenotype[38]  Arginine: 
Polyamines, Proline for 
proliferation/ repair[138, 
139] 
cDC + LPS Enhanced: Survival[26] and 
Cytokines[24] 
Enhanced: ROS, NO, Redox, 
RNA[140] 
Shut down via NO[26] 
Enhanced: Lipid 
production[140] 
Enhanced FAS: Phenotype 
maintenance[140] 
Arginine: NO production[26] 
pDC + CpG Delayed enhancement: 
Cytokine production[141] 
 Enhanced: Cytokine 
production[141] 
 Enhanced FAS & FAO: 
Cytokine production[141] 
 
Peritoneal ResMΦ 
(+phagocytosis) 
Enhanced: ATP 
production[64] 
Enhanced: ROS 
production[64] 
Enhanced: Phagocytosis, 
ROS production, microbial 
killing[64] 
Complex II enhanced: ROS 
production[64] 
Enhanced FAO after Il-4: 
Phenotype, 
proliferation[36] 
Glutamine & Glutamate: ROS 
production.  Basal arginase 
expression[64] 
Neutrophils/ 
gMDSC 
Enhanced: ATP 
production[64] 
Enhanced: ROS 
production[64] 
NET formation [95] 
NET formation, ROS[98] 
ATP production [91] 
 
 
Autophagic FAO: 
Differentiation[88] 
NADPH production for ROS 
T-cell Suppressive function 
(Rice 2018) [121] 
Glutamine not required for 
phagocytosis/ respiratory 
burst[64] 
Contributes to NET 
formation [97] 
TAM/  
mMDSCs 
Lactate stabilized HIF1a in 
TAMs[107] - induced 
glycolysis? 
   T-cell Suppressive function  
Arginine (via arginase) and 
Tryptophan (via IDO): T cell 
suppression in tumor[142-
145] 
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Table 1. Metabolic Pathways in Phagocytic Cell Subsets. The table denotes metabolic pathways 
utilized by specific phagocytic cells for cellular functions. (ROS, reactive oxygen species; NO, nitric 
oxide; FAO, fatty acid oxidation; FAS, fatty acid synthesis; ATP, adenosine triphosphate; TAM, 
tumor associated macrophage; CARKL, carbohydrate kinase-like protein; NET, neutrophil 
extracellular traps). 
 
 
 
Figure 1. Metabolic pathways of neutrophils and macrophages.  Macrophages and neutrophils 
utilize their differing metabolic capacities to maintain their effector function. In short lived, 
rapidly responding neutrophils, glucose is rapidly processed to form ATP via glycolysis and NADPH 
via the pentose phosphate pathway. These activities enable neutrophils to engage in chemotaxis, 
phagocytose and maintain respiratory burst via NADPH. Neutrophil NOX can be associated with 
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the plasma membrane, rather than the mitochondria. This glucose-maintained NADPH source is 
important for many ROS related functions such as NET formation, however fatty acid and 
glutamine fueled mitochondrial function has also been demonstrated to play a significant role in 
NET formation and the maintenance of ROS when glucose availability or NOX function is limited. 
Neutrophils also build and utilize glycogen, possibly to further aid function in glucose-depleted 
environments. Macrophages are also able to process glucose via glycolysis and the pentose 
phosphate pathway to maintain ATP and NADPH respectively. ATP-stimulation of macrophages 
helps maintain mitochondrial membrane potential, cell viability and induces cytokine expression. 
As a longer-lived cell, macrophages also contain significant mitochondrial capacity and utilize this 
to process glutamine and fatty acids. This mitochondrial capacity is enhanced during activation 
with IL-4 and reduced under IFN-g and LPS stimulation in a nitric oxide dependent mechanism. 
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